Aktienanalyse zu Zoetis Inc (ZTS)ZTSZoetis Inc

Zoetis Inc. is a global animal health company. The Company is focused on the discovery, development, manufacture and commercialization of medicines, vaccines, diagnostic products and services, biodevices, genetic tests and precision animal health. The Company operates through two segments: the United States (U.S.) and International. Within each of these operating segments, it offers a diversified product portfolio, including vaccines, anti-infectives, parasiticides, dermatology, pain and sedation, other pharmaceutical, and animal health diagnostics, for both companion animal and livestock customers. It directly markets its products in approximately 45 countries across North America, Europe, Africa, Asia, Australia and South America. The Company is engaged in commercializing products across eight species: dogs, cats and horses (collectively, companion animals) and cattle, poultry, swine, fish and sheep (collectively, livestock). It operates in the Healthcare sector (PHARMACEUTICAL PREPARATIONS industry).

Zoetis Inc (ZTS) appears to be a good buy right now, trading at $79.38 with a forward P/E of 11.99, which is attractive compared to the industry average. The stock has shown a 5-day change of +6.11%, indicating positive momentum. However, it has a significant risk with a year-to-date change of -36.96%, reflecting past volatility. Overall, the combination of a low valuation and recent insider buying trends suggests potential for recovery.

21 analysts cover ZTS: 14 rate it Buy, 7 Hold and 0 Sell. The average price target is 154.20.